Plasma protease C1-inhibitor treatment is a plasma-derived therapeutic used for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder characterized by episodes of severe swelling. Plasma protease C1-inhibitor treatment offers advantages such as reduced severity and frequency of HAE attacks.

The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to ... Read more

The plasma protease C1-inhibitor treatment market involves the use of plasma-derived and recombinant C1-inhibitor preparations for the treatment of hereditary angioedema (HAE). HAE is a rare genetic condition characterized by attacks of swelling in parts of the body like hands, feet, abdomen, face, airway, and throat. The swelling occurs due to low levels of C1-inhibitor, a blood protein. Plasma protease C1-inhibitor treatment helps control and prevent swelling attacks in patients with HAE. ... Read more